Lisata Therapeutics (NASDAQ: LSTA) — Company Overview, News & Financial Data
Lisata Therapeutics develops RNA-based therapies for cancer, enhancing patient care through innovative research and clinical trials.
Lisata Therapeutics
Lisata Therapeutics (NASDAQ:LSTA) is dedicated to developing innovative therapeutics for the treatment of cancer and other serious diseases. With a focus on crafting solutions that precisely target disease mechanisms, Lisata is at the forefront of creating next-generation treatments. Their projects span from early-stage research to advanced clinical trials, aiming to transform patient care and outcomes. Objectives include accelerating the development of their pipeline projects, expanding their research into new therapeutic areas, and establishing partnerships to enhance their reach and capabilities. Through relentless innovation and a commitment to excellence, Lisata Therapeutics strives to improve the quality of life for patients worldwide.
Snapshot
Operations
Products and/or services of Lisata Therapeutics
- Developing a unique delivery system for solid tumor treatment, leveraging targeted payload release.
- Advancing a novel oncology pipeline with proprietary technology aimed at improving cancer treatment outcomes.
- Creating personalized medicine solutions to enhance efficacy in cancer therapies.
- Innovating in drug delivery platforms to minimize side effects and optimize therapeutic impact.
- Collaborating on research projects with leading institutions to accelerate groundbreaking cancer treatments.
- Expanding into biotechnology services to support drug development and clinical trials for oncology.
Lisata Therapeutics executive team
- David J. MazzoCEO & Director
- James NiscoSVP of Finance and Treasury & Chief Accounting Officer
- Joshua Lehrer-GraiwerPresident & COO
Latest news about Lisata Therapeutics
Dividend history
Dividends per share paid by Lisata Therapeutics, by financial year.
| Financial year | Interim | Final | Special | Total |
|---|---|---|---|---|
| FY2013 | $0.3100 | — | — | $0.3100 |
| FY2010 | — | $0.2500 | — | $0.2500 |
Key financials
Reported results for Lisata Therapeutics, in USD.
- Market cap
- 11.8M
- Revenue (TTM)
- 100K
- P/E ratio
- —
- EPS (diluted, TTM)
- -1.6
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 170K | -18.2M | -16.6M | |
| 1M | -22.4M | -20M | |
| 0 | -25.7M | -20.8M | |
| 121.4M | -57.6M | -54.2M |